CD14 and breast carcinoma: However, all monocyte subpopulations investigated (total CD14+-, classical CD14++CD16-, intermediate CD14++CD16+- and non-classical CD14+CD16++ monocytes) were largely unaltered across breast cancer groups (Fig 1A–1D, see S1A Fig for representative dot plots).